Business Context and Reporting Period
This Form 8-K was filed by Protagonist Therapeutics, Inc. on March 19, 2019. The report addresses corporate governance changes, specifically the departure of a senior officer and the appointment of an interim replacement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Niall Murphy ceased serving as Vice President and Corporate Controller, including his role as Interim Principal Accounting Officer, effective March 19, 2019.
- Appointment: Dinesh V. Patel, Ph.D., the Company's President and Chief Executive Officer, was appointed as Interim Principal Accounting Officer effective March 20, 2019.
- Continuity: Dr. Patel will continue to serve as the Company's Interim Principal Financial Officer.
Management Commentary and Risks
Dr. Patel brings over 30 years of executive and scientific experience in the pharmaceutical and biotechnology industries. His background includes leadership roles at Aréte Therapeutics, Miikana Therapeutics, Versicor (acquired by Pfizer), Affymax, and Bristol-Myers Squibb. The Company stated that no new agreement was entered into with Dr. Patel for this appointment, nor were any existing agreements amended. No specific risks or contingencies were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of Dr. Patel's assumption of the Interim Principal Accounting Officer role (March 20, 2019).
- Verify that no additional compensation or contractual amendments were triggered by this appointment.
- Review subsequent filings to determine if a permanent Principal Accounting Officer has been appointed.